Investor Ideas, Trading Ideas and Stocks to Watch : #AIEye #Podcast Episode 560: #Stocks discussed: (NYSE: $YEXT) (NasdaqGS: $KRBP) #artificialintelligence

Monday, May 24, 2021

#AIEye #Podcast Episode 560: #Stocks discussed: (NYSE: $YEXT) (NasdaqGS: $KRBP) #artificialintelligence

#AIEye #Podcast Episode 560: #Stocks discussed: (NYSE: $YEXT) (NasdaqGS: $KRBP) #artificialintelligence

Yext Launches Support Answers, and Kiromic BioPharma Submits #AI-Derived IND Trial to FDA

Business Use of #AI Valued at $1.8T by 2027

Point Roberts WA, Vancouver BC – May 24, 2021 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2021/052421-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2021/artificial-intelligence/05241YEXT-KRBP.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (NYSE:YEXT) (NasdaqGS:KRBP)

AI search company Yext, Inc. (NYSE:YEXT) has announced the launch of Support Answers, “a suite of enterprise search solutions built for customer support teams.” This will employ modern, AI-powered solutions to provide answers to “a business's FAQs, product manuals, help articles, and more.” Marc Ferrentino, Chief Strategy Officer at Yext, said:

"Customers have consistently expressed their aversion to contacting customer support, but for the longest time, businesses have not had the technology powerful enough for them to resolve their issues independently. Today, that changes with the launch of Support Answers, which leverages our platform's multiple search algorithms to interpret people's intent and deliver contextually relevant, direct answers in a way that meets consumers' needs and expectations, and saves a business time and money."

Kiromic BioPharma, Inc. (NasdaqGS:KRBP) has submitted a novel Investigational New Drug (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial, derived from the company’s proprietary artificial intelligence neural network platform (Diamond AI), that “has the potential to be a universal CAR T-Cell therapy for any solid malignancy that expresses the biomarker Iso-mesothelin, with higher efficacy, higher safety, as well as lower manufacturing and distribution costs.” Maurizio Chiriva-Internati, CEO of Kiromic, explained:

Kiromic is in a unique position because its bioinformatic engine combines CancerDiff, a data-mining tool for the identification of tumor-preferred isoforms, with Diamond, an AI-driven immunogenic peptide identification system.

This combination allows Kiromic to identify targetable sections of a tumor isoform (peptides) that are a unique signature of cancer cells.

The advantage of Kiromic’s system is two-fold: 1) it saves time and money because it allows the prioritization of tumor-selective targets, and 2) it maximizes the likelihood of identifying targets that are safe by increasing the targeting specificity.

Business Use of AI Valued at $1.8T by 2027

A report published by Research and Markets analyzing the global Artificial General Intelligence market, finds that “the productivity gain potential for business use of AI represents approximately $1.8T in economic value by 2027.” A further excerpt from the report’s description indicates that this:

“…will be nine times more with the use of general-purpose AI solutions market as compared to today's silo AI approach. Productivity gains will be achieved by transactions conducted by AI autonomous agents or “bots”. It is estimated that more than 8% of the global economic activity in 2027 will be done autonomously by some kind of AI solution whereas this amounts to less than one percent today. This represents a dramatic rise in the use of AI for enterprise, industrial, and government automation.”

The report also projects variously that the embedded AI in building infrastructure and equipment will reach $18.1 globally by 2026, the general-purpose AI market will reach $4.25B globally by 2026 for enterprise apps and solutions, the global market for general-purpose AI support of big data and prescriptive analytics will reach $1.35B, and that over 35% of enterprise value will be directly or indirectly attributable to general-purpose AI solutions by 2027.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com